Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.

Merck launched a cash tender offer to acquire all outstanding shares of Terns Pharmaceuticals at $53.00 net per share, with the offer expiring one minute after 11:59 p.m. ET on May 4, 2026. The deal requires tendering of >50% of Terns shares, HSR clearance and other customary conditions; Terns’ board recommends acceptance and the transaction is expected to close in Q2 2026. Merck filed a Schedule TO and Terns filed a Schedule 14D-9; upon closing Terns will become a Merck wholly owned subsidiary.

Analysis

Merck's bid for a small-cap specialty biotech acts as a recalibration signal: scale players are willing to pay control premiums to buy late-stage or near-commercial niche assets rather than shoulder earlier-stage risk. That tendency should compress valuations for similarly positioned micro/mid-cap biotech with single-asset risk, while lifting M&A comps and forward takeout multiples for CRO/CMO providers that serve those programs.

Primary near-term dynamics are an event-arb (tight calendar window to capture spread) and a medium-term re-rating trade: acquirer's balance sheet flexibility is now partially committed, which raises the bar for Merck to pursue another large, transformational deal this year but increases the likelihood of more bolt-on purchases in focused therapeutic areas. Regulatory clearance and any outstanding clinical readouts remain the key binary catalysts — a smooth regulatory path keeps the spread tight, failure or litigation re-prices small-cap bio materially lower.

The consensus view treats this as a straightforward arbitrage; the contrarian risk is integration and attrition of target scientific talent which often erodes assumed synergies and delays commercialization by 12–24 months. Play size should therefore differentiate between capture of the short-term arbitrage spread (weeks) and a strategic reallocation into names exposed to increased M&A activity (months), with explicit downside protection for deal-failure scenarios.

Key Decisions for Investors

• Event-arb: Buy TERN shares up to a 2–4% spread capture threshold versus the tender consideration, tender shares into the offer and delta-hedge equity-market exposure (short XBI or a small-cap biotech basket). Timeframe: hold until tender closes (weeks). Risk/reward: target 20–60%+ annualized return on capital deployed if deal completes; downside if deal fails is large (60–80%); size position with strict buy-stop and purchase of protective puts to cap failure losses at ~20–30%.
• Hedged yield on acquirer: Sell covered calls on MRK sized to fund an opportunistic buy of out-of-the-money 6–9 month calls (buy-write). Timeframe: 3–9 months. Risk/reward: generate ~2–4% premium income over quarters while retaining upside exposure to modest re-rating; if pipeline or integration disappoints, downside capped by underlying position with defined call premium received.
• Pairs/M&A beta trade: Long small-cap CRO/CMO names with high exposure to niche oncology/rare-disease customers and short a broad healthcare ETF (XLV) to isolate M&A alpha. Timeframe: 3–12 months. Risk/reward: expect 10–30% upside for selected CRO/CMOs on elevated deal volumes; hedge macro/sector risk via the short ETF leg.
• Protection trade (cheap insurance): Buy deep OTM puts on TERN or buy-to-open a put spread to limit tail-loss from a deal break while retaining most upside from tender completion. Timeframe: events over weeks–months. Risk/reward: small premium (<2–3% of position) to cap catastrophic downside, preserving the majority of expected arbitrage return.